News – Sound Bioventures

All Events Fund articles Fund PR Portfolio articles Portfolio PR

AbolerIS Pharma Announces First Cohort Dosed in Phase 1 Study of ABO21009, a Novel Anti-CD45RC Antibody, for Rheumatoid Arthritis

2025.05.072025.05.07 / -Company is advancing a new class of immunomodulators for autoimmune and inflammatory disorders with high unmet medical need- - ABO21009’s unique mechanism of action depletes pathogenic T and B ce ...

Linda Spahiu Elvesjö

A polyglot with an international worldview of science and investment

2025.05.062025.05.06 / With previous roles like scientist and startup CEO, Linda Spahiu Elvesjö’s background is ideal for investing in companies that’ll make a difference in patients’ lives and provide strong returns. As P ...

AbolerIS Pharma Announces Formation of Scientific Advisory Board

2025.04.292025.04.30 / Gosselies, Belgium and Nantes, France, April 24, 2025 /PRNewswire/ -- AbolerIS Pharma (“AbolerIS”), a clinical-stage biopharmaceutical company committed to improving the lives of people suffering fro ...

Read about Artax Biopharma and their journey developing a revolutionary therapy for autoimmune diseases that makes a meaningful difference in patients lives.

Artax Biopharma to present Phase 2a data on Nck modulatorAX-158, establishing novel mechanism of action in autoimmune disease at the 2025 SID Annual Meeting

2025.04.252025.04.30 / Late breaker abstract presentation to showcase clinical validation of first-in-class oral small molecule AX-158 in cohort of patients with psoriasis Full dataset to expand on previously announced ...

Maximizing value when developing oncolytic viral therapy

2025.04.012025.04.30 / As the new CEO for Theolytics, David Apelian aims to take full advantage of the first clinical studies for the company’s lead product. The UK-based biotech has a whole potential platform for creating ...

AnaCardio receives patent grant in Europe for AC01

2025.03.132025.04.30 / Stockholm, Sweden and Lugano, Switzerland, March 13, 2025 - AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents to treat patients with heart failure and Helsinn ...

Read about Artax Biopharma and their journey developing a revolutionary therapy for autoimmune diseases that makes a meaningful difference in patients lives.

Artax Biopharma presents new preclinical data on Nck modulators at 2025 AAD Annual Meeting

2025.03.102025.04.30 / Nck modulator reduced evidence of inflammation in an animal model of dermal irritation Compelling preclinical data support continued development of Nck modulators in atopic dermatitis Cambridge ...

Read about Artax Biopharma and their journey developing a revolutionary therapy for autoimmune diseases that makes a meaningful difference in patients lives.

Artax Biopharma to present on first-in-class Nck modulator at the 2025 AAD Annual Meeting

2025.03.032025.04.30 / Poster presentation on evaluation of Nck modulator in atopic dermatitis models Cambridge, MA, March 3, 2025 – Artax Biopharma, Inc., a clinical-stage biotechnology company focused on tran ...

AnaCardio reports first patient dosed in the phase 2a study evaluating AC01 in patients with heart failure and reduced ejection fraction (HFrEF)

2025.02.272025.04.30 / February 25, 2025, Stockholm, Sweden - AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents to treat patients with heart failure today announced that the first pa ...

Applying the best of both science and business to treat heart failure

2025.01.312025.04.30 / AnaCardio is focused on bringing treatment for one of today’s largest unmet medical needs to market. According to CEO Patrik Strömberg, the Swedish biopharmaceutical company is leveraging strong scie ...

Read about Artax Biopharma and their journey developing a revolutionary therapy for autoimmune diseases that makes a meaningful difference in patients lives.

Artax Biopharma achieves clinical validation of first-in-class, oral, Nck modulator AX-158 for autoimmune disease in phase 2a study

2025.01.222025.04.30 / Novel breakthrough: first molecule to modulate the fundamental mechanism ofT cell activation underlying autoimmune pathology Statistically significant improvements in T cell and psoriasis-related ...

Sound Bioventures 2024 Year in Review

2025.01.212025.01.22 / Backed by our investors and partners, Sound Bioventures has in 2024 continued to grow our impactful trans-Atlantic portfolio of life-changing biotech companies. Guided by a commitment to advance heal ...